Reply to W. E. Rosa et al and T. N. Townsend et al

Andrea C Enzinger¹, Kaushik Ghosh¹, Nancy L Keating¹, David M Cutler¹, Mary Beth Landrum¹, Alexi A Wright¹

Affiliations

Affiliation

¹ Andrea C. Enzinger, MD, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Kaushik Ghosh, PhD, The New England Bureau of Economic Research, Cambridge, MA; Nancy L. Keating, MD, MPH, The Department of Healthcare Policy, Harvard Medical School, Boston, MA, The Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA; David M. Cutler, PhD, The New England Bureau of Economic Research, Cambridge, MA, The Department of Healthcare Policy, Harvard Medical School, Boston, MA, The Department of Economics, Harvard University, Boston, MA, The Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA; Mary Beth Landrum, PhD, The Department of Healthcare Policy, Harvard Medical School, Boston, MA; and Alexi A. Wright, MD, MPH, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

PMID: 34878818
DOI: 10.1200/JCO.21.02383

Comment

Reply to W. E. Rosa et al and T. N. Townsend et al

Andrea C Enzinger et al. J Clin Oncol. 2022.

. 2022 Jan 20;40(3):312-314.

doi: 10.1200/JCO.21.02383. Epub 2021 Dec 8.

Authors

Andrea C Enzinger¹, Kaushik Ghosh¹, Nancy L Keating¹, David M Cutler¹, Mary Beth Landrum¹, Alexi A Wright¹

Affiliation

¹ Andrea C. Enzinger, MD, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Kaushik Ghosh, PhD, The New England Bureau of Economic Research, Cambridge, MA; Nancy L. Keating, MD, MPH, The Department of Healthcare Policy, Harvard Medical School, Boston, MA, The Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA; David M. Cutler, PhD, The New England Bureau of Economic Research, Cambridge, MA, The Department of Healthcare Policy, Harvard Medical School, Boston, MA, The Department of Economics, Harvard University, Boston, MA, The Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA; Mary Beth Landrum, PhD, The Department of Healthcare Policy, Harvard Medical School, Boston, MA; and Alexi A. Wright, MD, MPH, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

PMID: 34878818
DOI: 10.1200/JCO.21.02383

No abstract available

PubMed Disclaimer

Conflict of interest statement

Andrea C. EnzingerConsulting or Advisory Role: Five Prime Therapeutics (I), Merck (I), Astellas Pharma (I), Lilly (I), Loxo (I), Taiho Pharmaceutical (I), Daiichi Sankyo (I), Zymeworks (I), Ono Pharmaceutical (I), Xencor (I) David M. CutlerExpert Testimony: MDL—JUUL Alexi A. WrightConsulting or Advisory Role: GlaxoSmithKlineResearch Funding: NCCN/AstraZenecaNo other potential conflicts of interest were reported.

Comment on

US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life.
Enzinger AC, Ghosh K, Keating NL, Cutler DM, Landrum MB, Wright AA. Enzinger AC, et al. J Clin Oncol. 2021 Sep 10;39(26):2948-2958. doi: 10.1200/JCO.21.00476. Epub 2021 Jul 22. J Clin Oncol. 2021. PMID: 34292766 Free PMC article.
Opioid Prescribing to Patients With Advanced Cancer: Unanswered Questions.
Townsend TN, Bohnert ASB, Merlin JS. Townsend TN, et al. J Clin Oncol. 2022 Jan 20;40(3):311-312. doi: 10.1200/JCO.21.02086. Epub 2021 Dec 8. J Clin Oncol. 2022. PMID: 34878802 No abstract available.
The US Cancer Pain Crisis and the Global Pain Divide: Can Two Wrongs Make It Right?
Rosa WE, Knaul FM, Pettus KI, Bruera E, Rajagopal MR. Rosa WE, et al. J Clin Oncol. 2022 Jan 20;40(3):310-311. doi: 10.1200/JCO.21.02049. Epub 2021 Dec 8. J Clin Oncol. 2022. PMID: 34878827 Free PMC article. No abstract available.

Publication types

Actions
Actions
Actions

MeSH terms

Actions

Grants and funding

U19 HS024072/HS/AHRQ HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to W. E. Rosa et al and T. N. Townsend et al

Affiliation

Reply to W. E. Rosa et al and T. N. Townsend et al

Authors

Affiliation

Conflict of interest statement

Comment on

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources